220 related articles for article (PubMed ID: 34136083)
1. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
Ellison V; Annor GK; Freedman C; Xiao G; Lundine D; Freulich E; Prives C; Bargonetti J
Oncotarget; 2021 Jun; 12(12):1128-1146. PubMed ID: 34136083
[TBL] [Abstract][Full Text] [Related]
2. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
[TBL] [Abstract][Full Text] [Related]
3. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
5. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
[TBL] [Abstract][Full Text] [Related]
6. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Polotskaia A; Xiao G; Reynoso K; Martin C; Qiu WG; Hendrickson RC; Bargonetti J
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1220-9. PubMed ID: 25733866
[TBL] [Abstract][Full Text] [Related]
7. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
Xiao G; Annor GK; Fung K; Keinänen O; Zeglis BM; Bargonetti J
Mol Pharm; 2021 Jan; 18(1):338-346. PubMed ID: 33289569
[TBL] [Abstract][Full Text] [Related]
8. A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN.
Ellison V; Polotskaia A; Xiao G; Leybengrub P; Qiu W; Lee R; Hendrickson R; Hu W; Bargonetti J
bioRxiv; 2024 Jan; ():. PubMed ID: 38328189
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
10. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
11. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.
Qiu WG; Polotskaia A; Xiao G; Di L; Zhao Y; Hu W; Philip J; Hendrickson RC; Bargonetti J
NPJ Breast Cancer; 2017; 3():. PubMed ID: 28232952
[TBL] [Abstract][Full Text] [Related]
12. Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer.
Berke TP; Slight SH; Hyder SM
Onco Targets Ther; 2022; 15():23-30. PubMed ID: 35035222
[TBL] [Abstract][Full Text] [Related]
13. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure.
Shi M; Shtraizent N; Polotskaia A; Bargonetti J; Matsui H
PLoS One; 2014; 9(6):e99351. PubMed ID: 24937470
[TBL] [Abstract][Full Text] [Related]
14. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.
Garufi A; Trisciuoglio D; Porru M; Leonetti C; Stoppacciaro A; D'Orazi V; Avantaggiati M; Crispini A; Pucci D; D'Orazi G
J Exp Clin Cancer Res; 2013 Oct; 32(1):72. PubMed ID: 24220325
[TBL] [Abstract][Full Text] [Related]
15. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Kong Y; Brown ML; Bae I
Oncotarget; 2013 Jul; 4(7):984-94. PubMed ID: 23846322
[TBL] [Abstract][Full Text] [Related]
16. An
Malami I; Muhammad A; Etti IC; Waziri PM; Alhassan AM
EXCLI J; 2017; 16():1276-1287. PubMed ID: 29333130
[TBL] [Abstract][Full Text] [Related]
17. Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β.
Takahashi RU; Takeshita F; Honma K; Ono M; Kato K; Ochiya T
Sci Rep; 2013; 3():2474. PubMed ID: 23959174
[TBL] [Abstract][Full Text] [Related]
18. Mutations in DNA binding domain of p53 impede RSL1D1-p53 interaction to escape from degradation in human colorectal cancer cells.
Ding L; Zhao C; Xu Y; Zhang Z; Nie Y; Liao K; Chen Y; Tu B; Zhang X
Exp Cell Res; 2022 Aug; 417(1):113211. PubMed ID: 35597299
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
20. ChIP-chip data for identifying target genes and consensus binding sequences of mutant p53 in MDA-MB-468 breast cancer cells.
Le MNU; Ning Y; Zhou J
Data Brief; 2023 Oct; 50():109499. PubMed ID: 37663770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
